NCT05933967View on ClinicalTrials.gov

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2026

Conditions
The First Affiliated Hospital of Nanchang University
Interventions
DRUG

Orelabrutinib+R-CHOP

Orelabrutinib 150mg qd PO. Rituximab 375 mg/m2 IV on Day 0 of each 21-day cycle. The CHOP include cyclophosphamide, doxorubicin/Epirubicin/liposomal doxorubicin, vincristine/Vindesine, and prednison.

Trial Locations (2)

Unknown

RECRUITING

The First Ailliated Hospital of Nanchang University, Nanchang

RECRUITING

Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan

All Listed Sponsors
collaborator

The First Affiliated Hospital of Nanchang University

OTHER

lead

Shandong Cancer Hospital and Institute

OTHER